Results 51 to 60 of about 28,830 (241)

Safety and Effectiveness of Glecaprevir/Pibrentasvir in Children and Adolescents With Chronic Hepatitis C: Reports From All‐Case Post‐Marketing Surveillance in Japan

Hepatology Research, EarlyView.
ABSTRACT Aim The aim of this all‐case post‐marketing study was to evaluate the real‐world safety and effectiveness in all children and adolescents with chronic hepatitis C with or without compensated cirrhosis treated with glecaprevir/pibrentasvir (G/P) in Japan. Methods This prospective, observational post‐marketing surveillance study was conducted at
Tatsuki Mizuochi, Katsuyoshi Kawana, Mariko Kobayashi, Eri Iwashita, Itaru Iwama, Daiki Abukawa, Hitoshi Tajiri   +6 more
wiley   +1 more source

Nevirapine versus Efavirenz for patients co-infected with HIV and Tuberculosis: A Randomised Non-Inferiority Trial

, 2013
BACKGROUND: In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antituberculosis drugs. We aimed to compare efficacy and safety of a nevirapine-
Nilesh Bhatt, Rui Bastos, Maryline Bonnet, Jani, Ilesh, Elizabete Nunes, Sobry, Agnès, Ilesh Jani, Baudin, Elisabeth, Silva, Carlota, Michon, Christophe, Bastos, Rui, Christophe Michon, Calmy, Alexandra, Carlota Silva, Nunes, Elizabete, Agnès Sobry, Bonnet, Maryline, Alexandra Calmy, Taburet, Anne-Marie, Bhatt, Nilesh, Rouzioux, Christine, Laura Ciaffi, Elisabeth Baudin, Ciaffi, Laura, Anne-Marie Taburet, Christine Rouzioux   +25 more
core   +1 more source

Temporal shifts in antiretroviral therapy regimens and metabolic outcomes in people living with HIV: A systematic review and meta‐analysis

HIV Medicine, EarlyView.
Abstract Introduction Antiretroviral therapy (ART) for people living with HIV has led to dramatically reduced mortality and improved life expectancy. This achievement is accompanied by a higher risk for metabolic and other non‐communicable diseases. The role and contribution of various ART regimens to adverse metabolic outcomes are not fully understood.
Melani Ratih Mahanani, Myo Chit, Sophie Mohr, Elisenda Cama i Gibernau, Svetlana Hetjens, Volker Winkler, Hans‐Michael Steffen, Florian Neuhann   +7 more
wiley   +1 more source

The rate of viral rebound after attainment of an HIV load < 50 copies/mL according to specific antiretroviral drugs in use: Results from a multicenter cohort study

, 2005
Background. Relatively few data are available on the association between the use of specific antiretroviral drugs and the rate of viral rebound in those attaining a viral load (VL) 500 copies/ mL).
Smith, CJ, Smith, C J, Phillips, AN, Porter, K, Scullard, G, Hill, T, Fisher, M, Phillips, A N, Easterbrook, P, Johnson, MA, Gilson, R, Sabin, C A, Gazzard, B, United Kingdom HIV Cohort Study, Matthias, R, Sabin, CA, Johnson, M A   +16 more
core   +1 more source

Clinical and electrophysiological characteristics of Efavirenz-induced macular toxicity

, 2020
Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, is commonly used to treat HIV-infected individuals. We report a case of painless, progressive and bilateral blurring of vision in an HIV-positive 54-year-old lady within months of ...
Banerjee, A, Sen, P, Dhami, A, Sudharshan, S   +3 more
core   +1 more source

HIV drug resistance and treatment success in the Republic of Congo: Implications for optimized treatment

HIV Medicine, EarlyView.
Abstract Objectives Increasing rates of HIV‐1 drug resistance (HIVDR) threaten the effectiveness of antiretroviral therapy (ART) programmes in sub‐Saharan Africa, particularly among children, adolescents and young adults, who face limited treatment options.
Dominic Rauschning, Arcy Marcelin Elenga Ike, Johanna Holterhoff, Amira Stockinger, Darrel Ornelle Elion Assiana, Claujens Chastel Mfoutou Mapanguy, Freisnel Hermeland Mouzinga, Carola Horn, Isabelle Suarez, Ferdinand Heyn, Diane Alexia Fila, Hubert Banguissa, Fabien Roch Niama, Donatien Moukassa, Eva Heger, Francine Ntoumi, Clara Lehmann   +16 more
wiley   +1 more source

Perspectives of healthcare professionals of the neuropsychiatric side effects associated with efavirenz and its management

Health SA Gesondheid: Journal of Interdisciplinary Health Sciences, 2018
Background: Efavirenz is associated with neuropsychiatric side effects. The consequences of using efavirenz in human immunodeficiency virus (HIV)-positive patients with mental illness has not been conclusively established, the concern being that ...
Razia Gaida, Ilse Truter, Christoffel Grobler   +2 more
doaj   +1 more source

Efavirenz and CYP2B6 polymorphism: Implications for drug toxicity and resistance

, 2006
No abstract ...
Nolan, D., Phillips, E., S. Mallal, E. Phillips, D. Nolan, Mallal, S.   +5 more
core   +1 more source

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont, Vanessa Bloch, Agnès Lillo‐Lelouet, Christine Le Beller, Pierre A. Geoffroy, Marc Veyrier   +5 more
wiley   +1 more source

Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems

Journal of Nanobiotechnology, 2018
Background Recent work has developed solid drug nanoparticles (SDNs) of efavirenz that have been demonstrated, preclinically, improved oral bioavailability and the potential to enable up to a 50% dose reduction, and is currently being studied in a ...
Neill J. Liptrott, Marco Giardiello, Tom O. McDonald, Steve P. Rannard, Andrew Owen   +4 more
doaj   +1 more source